FMS stock news · Fresenius Medical Care AG
Get alerts for FMS
Follow Fresenius Medical Care AG (FMS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for FMSMoody's gave Fresenius Medical Care's $1.0 billion US commercial paper program a P-3 short-term rating.
NeutralMoody's assigned a P-3 rating to Fresenius Medical Care's US commercial paper program. Existing ratings and the stable outlook stayed unchanged, so the story does not change the company's outlook.
Fresenius Medical Care is changing its plans in China to focus on specific products.
NeutralFresenius is narrowing its China product range and expects a one-time charge, but says revenue forecasts there will not change. The update leaves its outlook unchanged.
Fresenius faces criticism from the FDA regarding leaking dialysis bags, highlighting serious risks to patient safety.
Bad for FMSThe FDA has warned Fresenius Medical Care about serious manufacturing violations at its Ogden, Utah facility, particularly concerning leaking dialysis bags that could expose patients to life-threatening infections. The company is required to address these issues promptly to avoid further regulatory actions.